CL2012001835A1 - Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio. - Google Patents

Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.

Info

Publication number
CL2012001835A1
CL2012001835A1 CL2012001835A CL2012001835A CL2012001835A1 CL 2012001835 A1 CL2012001835 A1 CL 2012001835A1 CL 2012001835 A CL2012001835 A CL 2012001835A CL 2012001835 A CL2012001835 A CL 2012001835A CL 2012001835 A1 CL2012001835 A1 CL 2012001835A1
Authority
CL
Chile
Prior art keywords
moxifloxacin
formulation
middle ear
prepare
treating
Prior art date
Application number
CL2012001835A
Other languages
English (en)
Inventor
Roland J Sawchuk
Belinda W Y Cheung
Michael Wall
Original Assignee
Univ Minnesota
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306169&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001835(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Minnesota, Novartis Ag filed Critical Univ Minnesota
Publication of CL2012001835A1 publication Critical patent/CL2012001835A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Método de administración de moxifloxacina en el oído medio de un mamífero que comprende la aplicación de una formulación acuosa comprendiendo un agente viscogénico y moxifloxacina, la cual es fluida y tiene una viscosidad menor que los 100.000 CPS; y kit que comprende a la formulación e instrucciones para su aplicación.
CL2012001835A 2010-01-07 2012-07-06 Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio. CL2012001835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29301910P 2010-01-07 2010-01-07

Publications (1)

Publication Number Publication Date
CL2012001835A1 true CL2012001835A1 (es) 2013-03-22

Family

ID=44306169

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001835A CL2012001835A1 (es) 2010-01-07 2012-07-06 Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.

Country Status (23)

Country Link
US (1) US20120289541A1 (es)
EP (2) EP2521547B1 (es)
JP (3) JP2013516485A (es)
KR (2) KR101835895B1 (es)
CN (2) CN106309356A (es)
AU (1) AU2011204275B2 (es)
BR (1) BR112012016809A2 (es)
CA (1) CA2786525A1 (es)
CL (1) CL2012001835A1 (es)
CY (1) CY1119493T1 (es)
DK (1) DK2521547T3 (es)
ES (1) ES2644826T3 (es)
HR (1) HRP20171592T1 (es)
HU (1) HUE035586T2 (es)
LT (1) LT2521547T (es)
MX (1) MX337419B (es)
NO (1) NO2521547T3 (es)
PL (1) PL2521547T3 (es)
PT (1) PT2521547T (es)
RU (2) RU2016101214A (es)
SI (1) SI2521547T1 (es)
WO (1) WO2011085209A2 (es)
ZA (1) ZA201205965B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
DK2844309T3 (da) * 2012-06-28 2022-01-24 The Administrators Of The Tulane Educational Fund Selektivt polymeriserbare sammensætninger
CN103869033B (zh) * 2012-12-14 2016-10-05 南京长澳医药科技有限公司 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
WO2019113425A1 (en) * 2017-12-08 2019-06-13 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN108593696B (zh) * 2018-04-26 2020-11-03 南京明捷生物医药检测有限公司 一种利用定量核磁测定多肽中三氟乙酸残留的方法
CN117045593B (zh) * 2023-09-19 2024-05-28 上海市第六人民医院 一种用于慢性中耳炎治疗的抗菌温敏水凝胶及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
CN101072571A (zh) * 2004-12-10 2007-11-14 爱尔康公司 用于治疗耳感染的组合物
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof

Also Published As

Publication number Publication date
EP2521547A2 (en) 2012-11-14
CA2786525A1 (en) 2011-07-14
AU2011204275B2 (en) 2015-04-02
PL2521547T3 (pl) 2018-01-31
AU2011204275A1 (en) 2012-08-23
PT2521547T (pt) 2017-11-17
WO2011085209A2 (en) 2011-07-14
HUE035586T2 (en) 2018-05-28
RU2016101214A (ru) 2018-11-21
HRP20171592T1 (hr) 2018-02-09
SI2521547T1 (en) 2018-02-28
EP2521547B1 (en) 2017-08-16
JP2013516485A (ja) 2013-05-13
US20120289541A1 (en) 2012-11-15
EP2521547A4 (en) 2014-03-26
CN106309356A (zh) 2017-01-11
ES2644826T3 (es) 2017-11-30
RU2012133568A (ru) 2014-02-20
KR20120114344A (ko) 2012-10-16
JP6267246B2 (ja) 2018-01-24
CY1119493T1 (el) 2018-03-07
KR101835895B1 (ko) 2018-03-07
KR20180027611A (ko) 2018-03-14
JP2016155808A (ja) 2016-09-01
JP2018076352A (ja) 2018-05-17
NO2521547T3 (es) 2018-01-13
CN102791270A (zh) 2012-11-21
ZA201205965B (en) 2014-01-29
MX2012007928A (es) 2012-11-22
EP3305280A1 (en) 2018-04-11
WO2011085209A3 (en) 2011-11-17
BR112012016809A2 (pt) 2017-09-26
RU2576029C2 (ru) 2016-02-27
MX337419B (es) 2016-03-03
LT2521547T (lt) 2017-12-11
DK2521547T3 (da) 2017-11-20

Similar Documents

Publication Publication Date Title
CL2012001835A1 (es) Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
PE20150200A1 (es) Formulacion de anticuerpos
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
AR068867A1 (es) Composiciones de fluido para tratamianto de pozos que incluyen una formulacion de percarbonato de liberacion retardada y metodos para usarlas
BR112013001619A2 (pt) método, e, composição
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
DOP2012000245A (es) Composiciones sólidas
BR112013001027A2 (pt) agente de escoramento, e, métodos de formar um agente de escoramento para fraturar hidraulicamente uma formação subterrânea, e de fraturar hidraulicamente uma formação subterrânea
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BR112012013883A2 (pt) método
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
AR056500A1 (es) Metodo para preparar una composicion medica
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
AR098688A1 (es) Métodos para minimizar el sobredesplazamiento de apuntalante en tratamientos de fracturas
WO2014153009A3 (en) Thiosaccharide mucolytic agents
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição